Pharsight

1. Geodon patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5312925	VIATRIS	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride	Sep, 2012 (11 years ago)
US6245766	VIATRIS	Method of treating psychiatric conditions	Dec, 2018 (5 years ago)
US6150366	VIATRIS	Ziprasidone formulations	May, 2019 (4 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
M(M-232)	Jan 28, 2025
New Indication(I-615)	Nov 20, 2012

Market Authorisation Date: 05 February, 2001

Treatment: Treatment of bipolar disorder

Dosage: CAPSULE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
20 mg, 40 mg, 60 mg and 80 mg	07 Feb, 2005	5	02 Mar, 2012	27 May, 2019	Eligible

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5312925	PFIZER INC	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride	Sep, 2012 (11 years ago)
US6245766	PFIZER INC	Method of treating psychiatric conditions	Dec, 2018 (5 years ago)
US6150366	PFIZER INC	Ziprasidone formulations	May, 2019 (4 years ago)
US7175855	PFIZER INC	Ziprasidone suspension	May, 2020 (3 years ago)

Market Authorisation Date: 29 March, 2006

Treatment: Treatment of neuroleptic diseases; Treatment of bipolar disorder; Treatment of psychosis

Dosage: SUSPENSION;ORAL